These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 23534710)

  • 1. Effect of MUC1 siRNA on drug resistance of gastric cancer cells to trastuzumab.
    Deng M; Jing DD; Meng XJ
    Asian Pac J Cancer Prev; 2013; 14(1):127-31. PubMed ID: 23534710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.
    Raina D; Uchida Y; Kharbanda A; Rajabi H; Panchamoorthy G; Jin C; Kharbanda S; Scaltriti M; Baselga J; Kufe D
    Oncogene; 2014 Jun; 33(26):3422-31. PubMed ID: 23912457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression.
    Li G; Zhao L; Li W; Fan K; Qian W; Hou S; Wang H; Dai J; Wei H; Guo Y
    Oncotarget; 2014 Sep; 5(18):8317-29. PubMed ID: 25327561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
    Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR
    Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
    Fessler SP; Wotkowicz MT; Mahanta SK; Bamdad C
    Breast Cancer Res Treat; 2009 Nov; 118(1):113-24. PubMed ID: 19415485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catecholamine-Induced β2-adrenergic receptor activation mediates desensitization of gastric cancer cells to trastuzumab by upregulating MUC4 expression.
    Shi M; Yang Z; Hu M; Liu D; Hu Y; Qian L; Zhang W; Chen H; Guo L; Yu M; Song L; Ma Y; Guo N
    J Immunol; 2013 Jun; 190(11):5600-8. PubMed ID: 23630346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.
    Wu G; Li L; Qiu Y; Sun W; Ren T; Lv Y; Liu M; Wang X; Tao H; Zhao L; Cao J; He L; Li H; Gu H
    Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1625-1639. PubMed ID: 34586349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab.
    Eto K; Iwatsuki M; Watanabe M; Ida S; Ishimoto T; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
    Ann Surg Oncol; 2014 Jan; 21(1):343-50. PubMed ID: 24154840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer.
    Nam S; Chang HR; Jung HR; Gim Y; Kim NY; Grailhe R; Seo HR; Park HS; Balch C; Lee J; Park I; Jung SY; Jeong KC; Powis G; Liang H; Lee ES; Ro J; Kim YH
    Cancer Lett; 2015 Jan; 356(2 Pt B):880-90. PubMed ID: 25449779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calpain4 is required for activation of HER2 in breast cancer cells exposed to trastuzumab and its suppression decreases survival and enhances response.
    Kulkarni S; Saju L; Farver C; Tubbs R
    Int J Cancer; 2012 Nov; 131(10):2420-32. PubMed ID: 22377768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance.
    Zuo Q; Liu J; Zhang J; Wu M; Guo L; Liao W
    Sci Rep; 2015 Jun; 5():11634. PubMed ID: 26108989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced HER2-positive gastric cancer: current and future targeted therapies.
    Pazo Cid RA; Antón A
    Crit Rev Oncol Hematol; 2013 Mar; 85(3):350-62. PubMed ID: 23021388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.
    Zhao Y; Wang Z; Jiang Y; Yang C
    Cancer Lett; 2011 Dec; 313(1):54-63. PubMed ID: 21943825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer.
    Sampera A; Sánchez-Martín FJ; Arpí O; Visa L; Iglesias M; Menéndez S; Gaye É; Dalmases A; Clavé S; Gelabert-Baldrich M; Poulsen TT; Kragh M; Bellosillo B; Albanell J; Rovira A; Montagut C
    Mol Cancer Ther; 2019 Nov; 18(11):2135-2145. PubMed ID: 31484705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
    Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
    Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
    Barok M; Tanner M; Köninki K; Isola J
    Cancer Lett; 2011 Jul; 306(2):171-9. PubMed ID: 21458915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.
    Hamano S; Mori Y; Aoyama M; Kataoka H; Tanaka M; Ebi M; Kubota E; Mizoshita T; Tanida S; Johnston RN; Asai K; Joh T
    Cancer Lett; 2015 Jan; 356(2 Pt B):846-54. PubMed ID: 25444894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can strategies targeting cleaved MUC1 overcome resistance to trastuzumab?
    Araki K; Pegram M
    Breast Cancer Res Treat; 2011 Jun; 127(2):589-90. PubMed ID: 19834800
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.